


# For our shareholders

6	Letter from the CEO
10	Our Executive Board
11	Report of the Supervisory Board
18	WACKER on the capital market
22	Highlights from 2025



# Dear Shareholders,

The chemical industry is under pressure – worldwide, but in Europe in particular. Contrary to expectation, demand in many customer sectors remained weak in 2025. A key reason here was tremendous market uncertainty. Fueled by trade conflicts and geopolitical crises, this uncertainty led to subdued ordering behavior and the postponement of investments. As a result, we produced and sold less overall in 2025.

At the same time, we have to realize that we are not just dealing with an economic dip, but with fundamental changes. New competitors are entering the market and overcapacities for many standard chemical products are typical of the current situation. This is exacerbated by structural disadvantages in Europe, such as energy prices that are still far too high and are internationally uncompetitive, and excessive regulation. This puts us at a clear disadvantage compared to our competitors in the USA and Asia.

In view of this complex situation, we, like many other chemical companies, had to adjust downwards our original 2025 targets in the course of the year. With annual sales of €5.5 billion and EBITDA of around €530 million before special effects, we met both the adjusted forecast and market expectations. Nonetheless, even if we ultimately closed 2025 in line with expectations, one thing is clear: we cannot be satisfied with that. →



**Dr. Christian Hartel**  
President & CEO of  
Wacker Chemie AG

We want to save more than

**€300m**

a year

This is particularly true with regard to our net result for the year. Due to a series of valuation adjustments, this result was clearly negative at more than €-800 million in 2025. Owing to the negative net result and the current circumstances, the Supervisory and Executive Boards will not propose a dividend for 2025.

To get WACKER back on track for success, we launched PACE, the largest cost-cutting project in WACKER's history, last year, with the clear aim of significantly reducing costs and strengthening our competitiveness to lasting effect. In particular, we want to use PACE to reduce our production-related and administrative costs by over €300 million per year.

PACE will also involve a reduction in positions. More than 1,500 jobs will be reduced worldwide, most of which will be at our German sites. There is no way around the fact that we need to change if we are to remain successful on the market.

Change brings uncertainty. But above all, it offers opportunities too. The opportunity to firmly establish WACKER as one of the world's leading chemical companies and put it back on track for profitable growth. →

# We will successfully shape the transformation that lies ahead of us. Because we not only have the right products and solutions for the future, but above all the right team.

We have the potential for this. No question about it. Because we have answers to the big questions facing humanity. We provide solutions for renewable energy, electromobility, smart construction, healthcare, medical technology and nutrition. What is more, our products help our customers to meet their sustainability targets. They make a demonstrable contribution to reducing CO<sub>2</sub> and conserving resources.

In order to serve these megatrends, we continued to make targeted investments in 2025. Because saving alone is not enough. We must also invest in the future, drive innovation and create the basis for new, profitable growth. One example of this is our new production line for semiconductor-grade polysilicon, which went on stream in Burghausen in 2025. The new plant not only expands our capacities, but also further increases the quality of the material. This strengthens our position as the global market and quality leader for hyperpure polysilicon – which is used in semiconductors. Polysilicon made by WACKER can already be found in every other computer chip. This market, moreover, is growing steadily.

We also see growth opportunities in the field of biotechnology. Our focus is on biotechnological solutions for the pharmaceutical and food sectors. By opening our WACKER Biotechnology Center in Munich last year, we are able to expand our research capacities and reinforce our innovative strength.

At the same time, we are accelerating our growth in the chemical divisions. For example, we continued to drive forward our specialties strategy with the commissioning of two new production facilities for silicones in Tsukuba, Japan, and Jincheon, South Korea, in 2025. In addition, we are building a new production site in Karlovy Vary in the Czech Republic. This site will start producing room-temperature-curing high-performance silicones in 2026. Such grades play a particularly important role in electromobility and renewable energy applications. We will open the site in mid-2026. →

In order to develop our potential even better, we formulated three overarching strategic priorities in spring 2025 that show us the way forward.

First, we elevate our business model and value proposition. In our chemical divisions, our focus is on specialties. In the Polysilicon division, we are concentrating on the semiconductor market. In our life sciences division, Biosolutions, the focus is on biotech solutions.

Second, we unleash the potential of our structure and processes by working on becoming faster and more efficient. In doing so, we are leveraging the opportunities that digitalization, automation and AI offer us.

Third, we excel with our people and culture. Occupational safety forms the basis for everything we do. At the same time, we are working on becoming even more diverse and further honing our focus on performance.

Our strategy and the measures we have taken will take effect and put WACKER back on the road to success. In its more than 100-year history, WACKER has repeatedly proven that it can successfully adapt to new circumstances. That is why I am confident that we will also successfully shape the transformation that lies ahead of us. Because we not only have the right products and solutions for the future, but above all the right team to master the challenges. On behalf of the entire Executive Board, I would therefore like to thank our employees worldwide for their dedication and commitment in these turbulent times.

Circumstances will remain challenging in 2026. It is therefore all the more important that we now continue to consistently pursue the path we have taken. After all, the market waits for no one. Speed is increasingly becoming a key differentiating factor. That's why all our measures involve maximum speed. 2026 will be a year of implementation – embodied by spirit, speed and confidence.

On behalf of the entire Executive Board team, I would like to thank you for your trust in WACKER. •



**Dr. Christian Hartel**  
President & CEO of Wacker Chemie AG

## Our Executive Board



**Dr. Christian Hartel**  
President & CEO



**Angela Wörl**




**Dr. Tobias Ohler**



**Dr. Christian Kirsten**

**Dr. Peter-Alexander Wacker**  
Chair of the Supervisory Board  
of Wacker Chemie AG



# Dear Shareholders,

The global environment once again presented Wacker Chemie AG with numerous challenges in 2025, with underlying conditions dominated by ongoing geopolitical conflicts, uncertainty surrounding trade policy and weak demand in key customer sectors. The company's response to these complex and challenging issues has been decisive.

One of these responses came in the form of PACE, an extensive efficiency program that was launched last year. PACE will bear fruit over the coming fiscal years and make a key contribution to strengthening WACKER's competitiveness to lasting effect.

The company also refined its strategic focus by setting clear priorities going forward. The emphasis on specialty products in the chemical divisions, hyperpure semiconductor-grade polysilicon and innovative biotechnology solutions allows WACKER to remain well positioned for the future. →

This is why it continued to invest systematically in this strategic direction in 2025, despite challenging economic times. One notable example is the commissioning of a new production line for hyperpure semiconductor-grade polysilicon at the Burghausen site. At over €300 million, the new production facility represents the Group's largest single investment in the last ten years. The opening of the WACKER Biotechnology Center in Munich also created new research capacities for the manufacturing of biopharmaceuticals and ingredients for foods and food supplements. These examples showcase just how systematically the company is investing in attractive growth markets to lay the foundation for profitable growth in the years to come.

Even though the economic environment is more than likely to remain challenging in the current 2026 fiscal year, we are convinced that the company is on track to generate significant added value for all its stakeholders.

#### **Continuous dialogue with the Executive Board**

At WACKER, sound corporate governance and control are built on a relationship of trust between the Executive Board and Supervisory Board as they work closely together in the company's interest. In 2025, the Supervisory Board performed – with great diligence – the duties incumbent upon it under law, the Articles of Association and its own Rules of Procedure. The Supervisory Board was involved at an early stage in every decision of fundamental significance for the company.

In both written and oral reports, the Executive Board regularly provided the Supervisory Board with timely and comprehensive information on corporate planning, strategic development, business operations, and the current state of Wacker Chemie AG and the Group, including the risk situation, risk management, and compliance and sustainability issues. Beyond scheduled Supervisory Board meetings, the chair of the Supervisory Board remained in close contact with the Executive Board, especially with the CEO, conferring on issues of strategy, business development, risk exposure, risk management and compliance, and was kept informed of current trends, the business situation, and key business transactions. Any deviations from business plans and targets were explained to the Supervisory Board in detail.

Wherever required by statutory provisions or the Articles of Association, the Supervisory Board voted on the reports and proposals of the Executive Board after detailed examination and discussion. There was no need for additional monitoring measures, such as the inspection of corporate documents or the appointment of experts. →

The Supervisory Board held four meetings in 2025, two in the first half of the year and two in the second half. Specific agenda items were discussed without the Executive Board being present. All Supervisory Board meetings were in person. Between meetings, the Executive Board informed the Supervisory Board in detail by means of written reports about all projects and plans of particular importance to the Group. At its full meetings and in its committees, the Supervisory Board discussed in detail business transactions of importance to the company and referred to the reports submitted by the Executive Board. The full meetings were prepared by shareholder and employee representatives in their own separate sessions.

#### **The Supervisory Board's main areas of deliberation**

The development of sales, earnings and employment at Wacker Chemie AG and the Group, together with strategic development opportunities, were the subject of regular consultations in the full meetings of the Supervisory Board. Discussions centered in particular around the difficult economic environment and the need to safeguard earnings and liquidity, as well as the risk situation and risk management, with a focus on the following issues:

- Weak global demand coupled with fierce competition
- Adjusting and enhancing the corporate strategy in a challenging market environment
- Macroeconomic and geopolitical uncertainty and the resulting opportunities and risks for our business
- PACE cost-saving project
- Investment planning
- Innovation
- Financing activities

The Supervisory Board discussed the WACKER Group's plans for 2026 at its meeting of December 4, 2025. On that occasion, the Supervisory Board also dealt with medium-term corporate plans for 2026–2030. In addition, it discussed and approved the capital-expenditure budget for 2026.

#### **Work in the committees**

The Supervisory Board is assisted in its work by the committees it has constituted. WACKER's Supervisory Board has created three committees – an Audit Committee, an Executive Committee, and a Mediation Committee (the latter in accordance with Section 27 (3) of the German Co-Determination Act (MitbestG)). The tasks and the members of these committees are detailed in the

→ [declaration on corporate management](#). →

The Audit Committee met four times in person last year. In the presence of the auditors, it discussed the audit of the annual financial statements of Wacker Chemie AG and the Group for 2024 and the consolidated interim financial statements for the first half-year. It also examined the Group's quarterly financial figures as well as issues relating to risk management, the accounting process, the internal control systems, compliance, auditing, and the preparatory review of sustainability reporting. It monitored the audit, especially regarding quality, as well as the independence of the auditors and the additional services they performed. The Audit Committee also submitted a recommendation to the Supervisory Board for the latter's proposal to the 2025 Annual Shareholders' Meeting about appointing an auditor for any reviews of interim financial reports for 2026 in the period preceding the ordinary Annual Shareholders' Meeting for the 2026 fiscal year. The Audit Committee then awarded the auditing contract for 2025 as per the resolution of the ordinary Annual Shareholders' Meeting for the 2025 fiscal year.

The Executive Committee met twice in person in 2025. The committee members discussed recommendations to the Supervisory Board regarding compensation issues and the reappointment of Dr. Tobias Ohler and Dr. Christian Kirsten. The Mediation Committee did not need to be convened in the reporting year. The Supervisory Board was regularly informed about the committees' work.

### **Initial and Advanced Training**

The members of the Supervisory Board are called upon to take part in training courses at regular intervals and are responsible for meeting this obligation themselves. The company supports the members in their educational endeavors, in particular by granting them generous expense allowances, which can and should be used for further training, among other things. When they take office, new Supervisory Board members receive an information package about their rights and obligations; it also includes information sheets on insider-trading bans and on personal transactions by managers. Where necessary, they are also informed about significant changes in legislation and court rulings affecting their work, or are able to take part in internal information events.

### **Personalized disclosure of attendance at meetings**

Last year, two members were excused from one Supervisory Board meeting each and one member was excused from two meetings. Otherwise, all members of the Supervisory Board attended all of its meetings. Committee meetings were always attended by all members. Members' attendance at meetings of the Supervisory Board and at their respective committee meetings is disclosed in personalized form in the following table: →

<b>Full Supervisory Board</b>	<b>Attendance at meetings during period of office</b>
Dr. Peter-Alexander Wacker	4/4
Manfred Köppl	4/4
Prof. Andreas H. Biagosch	4/4
Dr. Gregor Biebl	4/4
Matthias Biebl	4/4
Prof. Patrick Cramer	2/4
Stefan Entholzner	4/4
Ingrid Heindl	3/4
Barbara Kraller	4/4
Dr. Benedikt Postberg	4/4
Harald Sikorski	4/4
Reinhard Spateneder	4/4
Ann-Sophie Wacker	3/4
Prof. Anna Weber	4/4
Dr. Susanne Weiss	4/4
Günter Zellner	4/4
<b>Executive Committee</b>	
Dr. Peter-Alexander Wacker	2/2
Manfred Köppl	2/2
Matthias Biebl	2/2
<b>Audit Committee</b>	
Dr. Peter-Alexander Wacker	4/4
Manfred Köppl	4/4
Prof. Anna Weber	4/4
<b>Mediation Committee</b>	
Dr. Peter-Alexander Wacker	0/0
Manfred Köppl	0/0
Prof. Andreas Biagosch	0/0
Barbara Kraller	0/0

## Corporate Governance

Last year, the Supervisory Board looked closely at corporate governance standards. At its meeting of December 4, 2025, the Supervisory Board, as scheduled, dealt with application of the German Corporate Governance Code and adopted the annual declaration of conformity that must be submitted jointly by the Executive and Supervisory Boards in accordance with Section 161 of the German Stock Corporation Act (AktG). This declaration is available on the company's website and is also included in the → [declaration on corporate management](#). →

Further information on corporate governance at WACKER can likewise be found in the → [declaration on corporate management](#).

At its December meeting, the Supervisory Board also conducted a self-assessment and found that it works efficiently – for example, due to the regular preliminary discussions regarding the Supervisory Board meetings, the comprehensive reports provided by the Executive Board and the detailed documents received well in advance of the meetings. Further information on the Supervisory Board's regular self-assessments can be found in the → [declaration on corporate management](#).

### **Audit of the annual financial statements of Wacker Chemie AG and the WACKER Group**

PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft, Munich, audited the annual financial statements of Wacker Chemie AG, the consolidated financial statements and the combined management report – including the Group Sustainability Report – for 2025. PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft has audited Wacker Chemie AG and the WACKER Group since 2024. The persons responsible for signing the audit are Dietmar Eglauer and Anita Botzenhardt.

The Supervisory Board's Audit Committee had awarded the auditing contract in accordance with the resolution of the Annual Shareholders' Meeting of May 7, 2025. The auditors conducted their audit in accordance with Section 317 of the German Commercial Code (HGB) and the EU Audit Regulation, and in compliance with German Generally Accepted Standards for Financial Statement Audits promulgated by the Institut der Wirtschaftsprüfer (IDW). They issued unqualified audit opinions.

The auditors also carried out a review with limited assurance of the Group Sustainability Report. Accordingly, no issues were identified that would indicate that the statement did not satisfy the statutory requirements in all material respects.

The financial-statement documents (including the auditors' reports, the combined management report – with the Group Sustainability Report – and the Executive Board's proposal for the distribution of profits) were submitted to all the Supervisory Board members in good time.

At its meeting of February 24, 2026, the Audit Committee examined and discussed in detail the combined management report for Wacker Chemie AG and the Group, including the Group Sustainability Report, as well as the auditors' reports. The full Supervisory Board, at its meeting of March 4, 2026, closely examined and discussed the relevant annual accounting documents – including the Group Sustainability Report – with knowledge and in consideration of both the report of the Audit Committee and the auditors' reports. The auditors, Dietmar Eglauer and Anita Botzenhardt, took part in the deliberations at both meetings. In addition, Hendrik Fink attended these meetings as the auditor responsible for the Group Sustainability Report.

The auditors reported on the main results of the audits – in particular, the key audit matters described in the auditors' reports and the outcome of the review of the Group Sustainability Report – and were available to answer questions and provide supplementary information. →

After concluding its own examination, the Supervisory Board has no objections to raise to the annual financial statements of Wacker Chemie AG, the consolidated financial statements, the combined management report for Wacker Chemie AG and the Group – including the Group Sustainability Report – or the auditors' reports.

The Supervisory Board therefore approves the annual financial statements of Wacker Chemie AG and the consolidated financial statements as of December 31, 2025 as prepared by the Executive Board. The annual financial statements of Wacker Chemie AG are hereby adopted. The Supervisory Board concurs with the Executive Board's proposal for the appropriation of net retained profit. In accordance with Section 162 (3) sentence 2 of the German Stock Corporation Act, the compensation report for 2025 was examined by the auditors to determine whether the disclosures required by law pursuant to Section 162 (1) and (2) of the German Stock Corporation Act were made.

#### **Changes in the composition of the Supervisory and Executive Boards**

There were no changes to the composition of Wacker Chemie AG's Executive and Supervisory Boards in 2025.

The Supervisory Board would like to thank every single WACKER employee for their commitment in 2025 and to extend special thanks to the Executive Board's members and the employee councils for their dedication and leadership in another very challenging year. •

Munich, March 4, 2026

The Supervisory Board

A handwritten signature in black ink, consisting of a large, stylized 'P' followed by 'A' and a horizontal line extending to the right.


**Dr. Peter-Alexander Wacker**  
Chair of the Supervisory Board of Wacker Chemie AG

# WACKER on the capital market in 2025

In 2025, the global economy was dominated by ongoing geopolitical tension and trade conflicts. Nevertheless, all major stock market indices performed well, with some recording double-digit percentage gains since the end of 2024.

The DAX40, Germany's benchmark index, recorded its best year since 2019, with a year-over-year increase of around 23 percent. German Mid Caps, too, performed positively overall. The MDAX rose by around 20 percent over the course of the year compared to the end of 2024.

WACKER share performance in 2025 (indexed to 100)<sup>1</sup>



<sup>1</sup> 100 = €70.4 (year-end closing price on Dec. 30, 2024)

Source: Xetra closing prices

Wacker Chemie AG's shares saw a largely stable performance in 2025. At the start of 2025, WACKER stock stood at €70.04 (year-end closing price on December 30, 2024). After a weak start to the year, the stock declined by about 13 percent and it traded at just under €61 in mid-January. The share price then bounced back, with very high trading volumes in some cases and rose to its year high of €87.18 (closing price on March 18, 2025). With the increasing tariff-related uncertainty, the unclear market-access restrictions for solar-grade polysilicon in the US and the downward trend for incoming orders in the chemical industry, the share price subsequently fell to its year low of €59.50 on April 9, 2025. Over the course of the year, the share price fluctuated largely in a range between €60 and €70. Despite the revision of the full-year 2025 guidance on July 18, 2025, the share price trend remained stable. WACKER stock closed trading at the end of the year at €69.35 on December 30, 2025. This was down 1 percent compared to the end of the previous year and corresponded to a market capitalization of around €3.45 billion.

The performance of WACKER's share price reflected persistently challenging market conditions. →

## Proposal on the appropriation of net retained profit

In accordance with regulations under commercial law, Wacker Chemie AG posts a net retained profit of €814.8 million for 2025. The Executive and Supervisory Boards will propose to the Annual Shareholders' Meeting that no dividend be distributed, since a negative result was posted for 2025.

## Dividend trends

€	2025 <sup>1</sup>	2024	2023
Dividend	0.00	2.50	3.00
Dividend yield (%) <sup>2</sup>	0.0	2.6	2.3
Volume-weighted average share price	67.68	94.83	131.56
Net result for the year after taxes (attributable to WACKER's shareholders) (million)	-821.1	241.0	313.6
Dividend payout (million)	0.0	124.2	149.0
Distribution ratio (%) <sup>3</sup>	n.a.	51.5	47.5

<sup>1</sup> Subject to being approved by the Annual Shareholders' meeting on May 6, 2026

<sup>2</sup> In relation to the weighted average share price of the previous year

<sup>3</sup> In relation to net income after taxes (attributable to WACKER's shareholders) (million)

## Market capitalization (as of December 31, 2025)

WACKER's year-end market capitalization based on shares outstanding was €3.45 billion (December 31, 2024: €3.48 billion).

## Trading volume

In the reporting year, the average daily trading volume for WACKER stock on Xetra, Germany's regional exchanges, Tradegate and Quotrix was approximately 176,868 shares, which was about 35 percent higher than the prior-year figure of 131,262 shares. Average daily turnover for the shares, however, was €11.97 million, down slightly year over year (2024: €12.41 million).

## Facts & figures on WACKER stock

€	
Year-high (on March 18, 2025)	87.18
Year-low (on Apr. 9, 2025)	59.50
Year-end closing price (on Dec. 30, 2024)	70.04
Year-end closing price (on Dec. 30, 2025)	69.35
Performance for the year (without dividend)	-1
Year-end market capitalization (shares outstanding; prior year 3.48) (billion)	3.45
Average daily trading volume <sup>1</sup> (prior year: 12.41) (million)	11.97
Earnings per share from continuing operations (prior year: 4.85)	-16.53
Dividend per share (proposal)	0.00
Dividend yield <sup>2</sup> (%)	n.a.


<sup>1</sup> Trading platforms (Xetra, Germany's regional exchanges, Tradegate and Quotrix)

<sup>2</sup> Dividend yield based on the average share price (weighted by volume) of €67.68 in 2025

### Shareholder structure

Wacker Chemie AG's largest shareholder remains Dr. Alexander Wacker Familiengesellschaft mbH, Munich. It held over 50 percent of the voting shares in Wacker Chemie AG in 2025, as in the previous year. Blue Elephant Holding GmbH (Bad Wiessee, Germany) had no voting-share changes to report in 2025 either, with its holding in Wacker Chemie AG remaining at over 10 percent.

### Shareholder structure in %



### Useful information on WACKER stock

ISIN	DE000WCH8881
WKN	WCH888
Frankfurt Stock Exchange	WCH
Bloomberg	CHM/WCH.GR
Reuters	CHE/WCHG.DE
Initial public offering	April 10, 2006
Capital stock	€260,763,000
Trading segment	Regulated market (Prime Standard), Frankfurt/Main Stock Exchange
Category of shares	Bearer shares
Number of shares (Dec. 31, 2025)	52,152,600
Number of shares outstanding	49,677,983
Paying agent	Deutsche Bank, Frankfurt/Main

### **WACKER communicates closely with capital markets**

Key elements of corporate strategy are sustainability and a focus on specialty chemicals. These priorities are reinforced through continuous and open communication with institutional investors, private investors and analysts.

At the end of 2025, 19 analysts were covering WACKER (2024: 18 analysts). The consensus price target of analysts for WACKER stock declined during the year. At the beginning of the year, the average price target for WACKER stock was €113.72 (18 estimates, December 2024). At the end of 2025, the average price target was €68.21 (19 estimates), about 40 percent lower than at the beginning of the year.

### **Banks and investment firms covering and rating WACKER**

- Baader Europe / Alphavalue
- Bank of America
- Barclays
- Berenberg
- Citigroup
- Deutsche Bank
- DZ Bank
- Exane BNP Paribas
- HSBC
- Jefferies International
- J.P. Morgan
- Kepler Chevreux
- Landesbank Baden-Württemberg
- Metzler Bank
- MWB Research
- Morgan Stanley
- Oddo BHF
- UBS AG
- Warburg Research

On our website, we regularly report consensus analyst expectations for the current year. Moreover, our website offers extensive information on WACKER stock. In addition to the Annual Report, other financial reports, a Fact Book, presentations and publications (viewable online or downloadable), our website lists all our key financial-calendar dates and contact persons.



Discover our [financial calendar](#) online

## 01 Strengthening specialties business in Asia

**January** WACKER's new production plants for specialty silicones went on stream in Tsukuba, Japan, and in Jincheon, South Korea. This makes it possible to meet even better the growing demand for specialty silicones for the automotive sector, especially in relation to heat-sink compounds for electromobility applications, and for the construction industry. The new plants further strengthen WACKER's position in the Japanese and other Asian markets.

## 02 Top grade for climate protection

**February** For the second year in a row, WACKER achieved a top score of A in the Climate category of the CDP's annual sustainability ratings. CDP is a non-profit organization that evaluates the transparency and performance of organizations in the categories of Climate, Water and Forests.

## 03 Moving toward the production of green silicon

**March** WACKER's Holla site in Norway began replacing fossil coal with biocarbon as part of its silicon production process. The process of reducing quartz to metallurgical-grade silicon produces CO<sub>2</sub> emissions. But by using biocarbon, WACKER avoids fossil CO<sub>2</sub> emissions, thereby moving a considerable step closer to being able to produce "green" silicon.



## 04 Sustainable solutions at the ECS

**March** WACKER presented numerous product innovations at the European Coatings Show (ECS) in Nuremberg. Over 300 square meters, the company demonstrated its expertise as a leading manufacturer of specialty chemicals. Areas of focus included alpha-silane crosslinking binders for sealants and (assembly) adhesives as well as sustainable solutions for the building-materials sector.

## 05 Global safety initiative

**March** Safety is not an option, but a pre-condition for everything we do at WACKER and the common denominator that unites us all. Rules of conduct and principles that apply across the Group underline this requirement as part of a “for our safety” initiative and further strengthen our corporate safety culture.



## 06 Carbon footprint for product range

**May** WACKER provides customers with comparable data on the sustainability of its products. This information is based on “cradle-to-gate” production and emission data for everything WACKER produces. Dedicated software uses this data to calculate the specific and comparable carbon footprint for each product. Emissions are calculated with high data quality on the basis of actual material consumption rates.

## 07 In China for China

**May** WACKER continues to expand its position in the world’s largest chemical market: additional production lines for silicone fluids, silicone emulsions and elastomer gels went on stream at its Zhangjiagang site. What is more, to strengthen its specialty business, WACKER opened a new technology center in Jining in partnership with SICO Performance Material.

## 08 Alexander Wacker Innovation Award

**May** Every year since 2006, WACKER has honored excellent achievements in Research and Development with the Alexander Wacker Innovation Award. In 2025, this internal award was presented in two categories for the first time. The “Silicon eye,” which uses infrared cameras and artificial intelligence to produce a live image from a silicon furnace for the first time, was honored in the Scientific Excellence category. The use of a digital twin to depict the virtual commissioning of the new semiconductor-grade silicon cleaning line was honored in the Business Success category.

## 09 WACKER Silicone Award for Lutz Greb

**June** Lutz Greb, professor at Heidelberg University's Institute of Inorganic Chemistry, was presented with the WACKER Silicone Award. Since 1987, this award has been presented to outstanding researchers in the field of silicone-based and silicon-containing chemistry every two years. Internationally speaking, Greb's research in the field of complex chemistry and molecular catalysis is groundbreaking.

## 10 New Biotechnology Center opened

**July** WACKER has combined and strengthened its biotech research activities. 1,500 square meters of laboratory and pilot plant space and 700 square meters of office space have therefore been added at the Corporate R&D site in Munich. Research there focuses on manufacturing processes for biopharmaceuticals and on ingredients for food and dietary supplements.

## 11 Etching Line Next launched in Burghausen

**July** WACKER commissioned a new production line for high-purity semiconductor-grade polysilicon at its Burghausen site, further strengthening its position as a global quality and technology leader. Ultrapure polycrystalline silicon is the purest man-made material and the key raw material for the next generation of computer chips. Worth over €300 million, the new production facility represents the Group's largest single investment in the last ten years.



## 12 WACKER opens its doors

**September** More than 20,000 visitors took the opportunity to look behind the scenes at WACKER's two largest chemical sites in Germany: Burghausen and Nünchritz. Local residents, visitors and employees along with their families were able to gain inspiring first-hand insights into the diverse product range and operational processes of a leading chemical company.

## 13 50 years of WACKER in Mexico

**September** Half a century ago, WACKER established its first Central America sales office in Mexico City. Today, the Mexican subsidiary is the number one for polymer binders and silicones in Mexico and the region.

## 14 High-tech at K 2025

**October** Silicones from WACKER drive the world forward. Whether energy transition, e-mobility, digitalization or sustainability – WACKER has the right solutions for these megatrends. Visitors to WACKER's booth at K 2025, the world's largest plastics trade fair, in Düsseldorf, were able to see this for themselves.



## 15 Biotech for cultivated meat

**November** WACKER launched a growth factor that enables the growth of muscle, fat and connective tissue cells in culture media – the basis for the production of sustainable, cultivated meat. “FGF-2 Food” was developed for use in the production of cultivated meat. By cultivating animal cells, produced in a controlled environment, it is a sustainable and humane alternative to conventional meat production.

## 16 20 years of WACKER's Relief Fund

**December** The WACKER Relief Fund was founded in 2005 in response to the devastating tsunami in Asia. A great deal of good has been done since then. This is based on numerous donations from WACKER employees, which are then matched by the company. In line with the motto “helping people to help themselves,” the fund mainly focuses on supporting educational projects, such as the construction and running of schools in regions hit by natural disasters.